CL2009001195A1 - Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune. - Google Patents

Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.

Info

Publication number
CL2009001195A1
CL2009001195A1 CL2009001195A CL2009001195A CL2009001195A1 CL 2009001195 A1 CL2009001195 A1 CL 2009001195A1 CL 2009001195 A CL2009001195 A CL 2009001195A CL 2009001195 A CL2009001195 A CL 2009001195A CL 2009001195 A1 CL2009001195 A1 CL 2009001195A1
Authority
CL
Chile
Prior art keywords
individual
treating
immune
vaccine
enhancing
Prior art date
Application number
CL2009001195A
Other languages
English (en)
Spanish (es)
Inventor
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2009001195A1 publication Critical patent/CL2009001195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2009001195A 2008-05-16 2009-05-15 Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune. CL2009001195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5394708P 2008-05-16 2008-05-16

Publications (1)

Publication Number Publication Date
CL2009001195A1 true CL2009001195A1 (es) 2010-06-11

Family

ID=40823320

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001195A CL2009001195A1 (es) 2008-05-16 2009-05-15 Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.

Country Status (17)

Country Link
US (4) US9750729B2 (enExample)
EP (3) EP2296650B1 (enExample)
JP (3) JP5779091B2 (enExample)
KR (1) KR20110022608A (enExample)
CN (1) CN102099035A (enExample)
AU (1) AU2009246347A1 (enExample)
BR (1) BRPI0912692A2 (enExample)
CA (1) CA2724720A1 (enExample)
CL (1) CL2009001195A1 (enExample)
EA (1) EA201071316A1 (enExample)
ES (2) ES2882855T3 (enExample)
IL (1) IL209203A0 (enExample)
MA (1) MA32388B1 (enExample)
MX (1) MX2010012231A (enExample)
TW (1) TW201006834A (enExample)
WO (1) WO2009140447A1 (enExample)
ZA (1) ZA201008176B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP2296650B1 (en) * 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
JP4995211B2 (ja) * 2008-09-29 2012-08-08 キヤノン株式会社 電子写真画像形成装置
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
KR20160030099A (ko) * 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2017253560B2 (en) * 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
WO2020027225A1 (ja) * 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
ES2415336T3 (es) * 2003-04-11 2013-07-25 Survac Aps Vacuna terapéutica contra el cáncer
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1723122B1 (en) * 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
EP1749558A4 (en) 2004-05-02 2008-03-12 Sega Corp GAME SYSTEM
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
US20090005411A1 (en) 2005-12-20 2009-01-01 Novartic Ag Combinations of Organic Compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AU2007307763A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
RU2009118487A (ru) * 2006-10-19 2010-11-27 Новартис АГ (CH) Органические соединения
KR20090087094A (ko) * 2006-11-28 2009-08-14 노파르티스 아게 Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물
EP2126188A1 (en) 2006-12-26 2009-12-02 Arçelik Anonim Sirketi A washer / dryer with output from humidity sensor selectively input to control unit
WO2008109057A1 (en) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
EP2296650B1 (en) * 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors

Also Published As

Publication number Publication date
EA201071316A1 (ru) 2011-06-30
US20110135691A1 (en) 2011-06-09
MA32388B1 (fr) 2011-06-01
AU2009246347A1 (en) 2009-11-19
MX2010012231A (es) 2011-02-18
EP2296650A1 (en) 2011-03-23
ZA201008176B (en) 2011-08-31
US20200345714A1 (en) 2020-11-05
JP2016094429A (ja) 2016-05-26
US9750729B2 (en) 2017-09-05
CN102099035A (zh) 2011-06-15
BRPI0912692A2 (pt) 2017-03-21
EP2698158A1 (en) 2014-02-19
EP2698158B1 (en) 2021-06-30
JP2011524339A (ja) 2011-09-01
US20220296581A1 (en) 2022-09-22
JP5986655B2 (ja) 2016-09-06
EP2296650B1 (en) 2020-05-06
WO2009140447A1 (en) 2009-11-19
KR20110022608A (ko) 2011-03-07
JP5779091B2 (ja) 2015-09-16
ES2882855T3 (es) 2021-12-02
CA2724720A1 (en) 2009-11-19
US11382905B2 (en) 2022-07-12
JP2015129170A (ja) 2015-07-16
IL209203A0 (en) 2011-01-31
EP3701947A1 (en) 2020-09-02
JP6030739B2 (ja) 2016-11-24
US10786491B2 (en) 2020-09-29
TW201006834A (en) 2010-02-16
US20170368047A1 (en) 2017-12-28
ES2791957T3 (es) 2020-11-06

Similar Documents

Publication Publication Date Title
PH12021550052A1 (en) Methods of treating and preventing graft versus host disease
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
MX2011003843A (es) Incorporacion de adyuvante en inmunonanoterapeuticos.
CY1116435T1 (el) Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
CR20150242A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
EP2061504A4 (en) COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES
BRPI1013957A2 (pt) método para produzir exossomas moduladores imunes específicos, composição farmacêutica, exossoma, e, método para tratar um indivíduo em necessidade do tratamento.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
ATE528013T1 (de) Impfstoff-zusammensetzungen
BR112014014319A2 (pt) composições de cuidado oral
BRPI0820258A2 (pt) composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.